U.S. pharma huge copyright scrapped two experimental weight loss drugs past calendar year—a once-every day tablet, lotiglipron, due to elevated liver enzymes in addition to a 2 times-each day tablet, danuglipron, due to strong Unintended effects—but CEO Albert Bourla has mentioned the company is determined to “play and gain” during the obes